Epilepsy, a chronic neurological disorder characterized by recurrent, unprovoked seizures, poses significant challenges to healthcare professionals. Despite the availability of numerous antiepileptic drugs (AEDs), about one-third of patients continue to experience uncontrolled seizures. This article aims to provide an update on the latest advancements in epilepsy management.
The last decade has seen the introduction of several new-generation AEDs. These drugs, such as perampanel and brivaracetam, have demonstrated improved efficacy and tolerability. They act on novel targets, thus providing additional therapeutic options for patients with drug-resistant epilepsy. However, their long-term safety profiles remain to be fully established.
Neuromodulation therapies, such as Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), and Responsive Neurostimulation (RNS), have emerged as effective adjunctive treatments for drug-resistant epilepsy. These therapies modulate neuronal activity, thereby reducing seizure frequency and severity. While invasive, they offer substantial benefits for patients who are not surgical candidates or have failed epilepsy surgery.
Advances in genetic testing have revolutionized the diagnostic approach to epilepsy. By identifying the genetic basis of certain epilepsy syndromes, healthcare professionals can provide more personalized treatment plans. These advancements also hold promise for the development of targeted therapies.
Telemedicine has emerged as a vital tool in epilepsy management, particularly amidst the COVID-19 pandemic. It allows for remote patient monitoring, reducing the need for hospital visits, and facilitating timely intervention. Moreover, it enables wider access to specialized epilepsy care, especially for patients in remote areas.
Advancements in epilepsy management are transforming the landscape of patient care. While challenges remain, these innovations offer hope for improved seizure control and quality of life for patients with epilepsy. Healthcare professionals must stay abreast of these developments to provide optimal patient care.
1.
Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit
2.
La interacción GBP3-STING en el glioblastoma coordina la respuesta deficiente al temozolomide.
3.
SBRT vs IMRT: Better for Bowel Symptoms, Not Cancer Control
4.
Breast Cancer Genetic Testing Need in Black Women Identified
5.
Preoperative Embolization Linked to Relapse-Free Survival in Meningioma
1.
ctDNA in Aggressive B-Cell Lymphoma: Redefining MRD and Prognostic Monitoring
2.
Pediatric Cancer Cell Line Authentication and Reproducibility
3.
Surgical Innovation Using Hematopoietic Reserve Preservation During Major Surgery
4.
3D Genome Reorganization in Cancer Cells: Mechanisms, Clinical Implications, and Emerging Therapeutic Frontiers
5.
Cancer Immunotherapy: Advances, Guidelines, and Practical Tools for Modern Oncology Practice
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
2.
Thromboprophylaxis In Medical Settings
3.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
5.
Predicting Delayed Hemolytic Transfusion Reactions Through Donor-Recipient Antigen Exposure Modeling
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation